Domenica Donatella Li Puma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Domenica Donatella Li Puma has a total of 110 co-authors. Here are the top co-authors by number of shared publications:
- Claudio Grassi
Department of Neuroscience, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
17 shared publications - Roberto Piacentini
Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy
14 shared publications - Cristian Ripoli
Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy
9 shared publications - Giovanna De Chiara
Institute of Translational Pharmacology, CNR, Rome, Italy
5 shared publications - Anna Teresa Palamara
Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy
4 shared publications - Maria Elena Marcocci
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Rome, Italy
4 shared publications
Latest Publications
- Open Access
- 14 April 2026
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (11) , 5428-5437
Neuroinflammatory responses and synaptic impairment in a Herpes simplex virus type 1 model of sporadic Alzheimer’s disease
Alzheimer's disease is a progressive neurodegenerative disorder in which neuroinflammation has emerged as a key contributor to early synaptic and cognitive dysfunction. In previous studies, we demonstrated that the spread of herpes simplex virus type 1 infection to the central nervous system and its reactivation induced by thermal stress, triggers the accumulation of Alzheimer's disease molecular hallmarks and the development of an Alzheimer's disease-like phenotype in wild-type C57BL/6 mice. In particular, two cycles of thermal stress-induced reactivation in wild-type mice induced a marked upregulation of the proinflammatory cytokine interleukin-1β, along with hippocampal synaptic and memory deficits, features reminiscent of an early stage of neurodegeneration. Notably, blocking interleukin-1β signaling with anakinra, a pharmacological interleukin-1 receptor antagonist, fully rescued all structural and functional indices of neurodegeneration, highlighting the central role of neuroinflammation in early phases of the disease. Here, we documented that, in addition to increased interleukin-1β levels, two cycles of thermal stress promoted the activation of glycogen synthase kinase 3β through phosphorylation of the tyrosine residue at position 216 (Tyr216), along with elevated phosphorylation of its direct substrates, amyloid precursor protein (APP) at threonine 668 and tau at Serine 199. To dissect the contribution of APP and tau to herpes simplex virus type 1-induced synaptic dysfunction, we employed APP -/- and Tau -/- mice. After two cycles of thermal stress, these knock-out mouse models exhibited lower increases in interleukin-1β levels and smaller synaptic deficits than infected wild-type mice, along with a distinct profile of microglial activation. To determine whether neuroinflammation remains the predominant pathological driver at later stages, we extended our analyses to herpes simplex virus type 1-infected wild-type mice subjected to six cycles of thermal stress (6TS), which recapitulate an advanced disease stage with features reminiscent of an Alzheimer's disease-like phenotype. Although interleukin- 1β levels remained persistently elevated in mice subjected to six cycles of thermal stress, anti-inflammatory treatments with either anakinra or dexamethasone failed to rescue synaptic and memory deficits, suggesting that neuroinflammation was no longer the primary pathological driver. Instead, synaptic failure correlated with a pronounced increase in glycogen synthase kinase 3β-induced APP cleavage products (e.g., amyloid-β) and hyperphosphorylated tau, indicating a stage-dependent shift in pathogenic mechanisms, whereby early neuroinflammatory responses are progressively replaced by other processes primarily mediated by glycogen synthase kinase 3β. These findings underscore the stage-specific contribution of interleukin-1β and glycogen synthase kinase 3β to herpes simplex virus type 1-induced Alzheimer's disease-like synaptic failure, highlighting the importance of a phase-specific therapeutic strategy.
- 14 April 2026
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 21 (11) , 5428-5437
Open AccessNeuroinflammatory responses and synaptic impairment in a Herpes simplex virus type 1 model of sporadic Alzheimer’s disease
Alzheimer's disease is a progressive neurodegenerative disorder in which neuroinflammation has emerged as a key contributor to early synaptic and cognitive dysfunction. In previous studies, we demonstrated that the spread of herpes simplex virus type 1 infection to the central nervous system and its reactivation induced by thermal stress, triggers the accumulation of Alzheimer's disease molecular hallmarks and the development of an Alzheimer's disease-like phenotype in wild-type C57BL/6 mice. In particular, two cycles of thermal stress-induced reactivation in wild-type mice induced a marked upregulation of the proinflammatory cytokine interleukin-1β, along with hippocampal synaptic and memory deficits, features reminiscent of an early stage of neurodegeneration. Notably, blocking interleukin-1β signaling with anakinra, a pharmacological interleukin-1 receptor antagonist, fully rescued all structural and functional indices of neurodegeneration, highlighting the central role of neuroinflammation in early phases of the disease. Here, we documented that, in addition to increased interleukin-1β levels, two cycles of thermal stress promoted the activation of glycogen synthase kinase 3β through phosphorylation of the tyrosine residue at position 216 (Tyr216), along with elevated phosphorylation of its direct substrates, amyloid precursor protein (APP) at threonine 668 and tau at Serine 199. To dissect the contribution of APP and tau to herpes simplex virus type 1-induced synaptic dysfunction, we employed APP -/- and Tau -/- mice. After two cycles of thermal stress, these knock-out mouse models exhibited lower increases in interleukin-1β levels and smaller synaptic deficits than infected wild-type mice, along with a distinct profile of microglial activation. To determine whether neuroinflammation remains the predominant pathological driver at later stages, we extended our analyses to herpes simplex virus type 1-infected wild-type mice subjected to six cycles of thermal stress (6TS), which recapitulate an advanced disease stage with features reminiscent of an Alzheimer's disease-like phenotype. Although interleukin- 1β levels remained persistently elevated in mice subjected to six cycles of thermal stress, anti-inflammatory treatments with either anakinra or dexamethasone failed to rescue synaptic and memory deficits, suggesting that neuroinflammation was no longer the primary pathological driver. Instead, synaptic failure correlated with a pronounced increase in glycogen synthase kinase 3β-induced APP cleavage products (e.g., amyloid-β) and hyperphosphorylated tau, indicating a stage-dependent shift in pathogenic mechanisms, whereby early neuroinflammatory responses are progressively replaced by other processes primarily mediated by glycogen synthase kinase 3β. These findings underscore the stage-specific contribution of interleukin-1β and glycogen synthase kinase 3β to herpes simplex virus type 1-induced Alzheimer's disease-like synaptic failure, highlighting the importance of a phase-specific therapeutic strategy.
- Open Access
- 29 September 2025
- Published by Wiley in Advanced Materials
- Vol. 38 (3) , e13858
Lithium‐Charged Gold Nanoparticles: A New Powerful Tool for Lithium Delivery and Modulation of Glycogen Synthase Kinase 3 Activity
“A Trojan Horse for Lithium Delivery” . Lithium has important pharmacological applications, although its use is severely limited due to its narrow therapeutic window of administrable concentrations. This study presents a novel nanocarrier for this metal cation based on glutathione‐stabilized gold nanoparticles (LiG‐AuNPs), which enable targeted release of lithium. LiG‐AuNPs are easily synthesized, with dimensions of ≈2 nm, with a lithium loading of 2 wt%. These particles show a tendency to aggregate and a narrow size distribution. Aggregates of LiG‐AuNPs (a‐LiG‐AuNPs) are non‐toxic to cells at concentrations lower than 2 mg mL −1 and are rapidly internalized into cells, where they release lithium in the cytosol through cation exchange, effectively modulating Glycogen Synthase Kinase‐3 (GSK‐3β) activity, especially the β isoform. Administration of a‐LiG‐AuNPs in murine models increased the inhibitory phosphorylation of GSK‐3β at Ser9. Intranasal administration of a‐LiG‐AuNPs modulated GSK‐3β activity in the brain, particularly in the hippocampus, without significantly altering plasma lithium levels, even when the administration lasted several months. LiG‐AuNPs thus represent a powerful tool for the targeted administration of lithium, enhancing its therapeutic effects in modulating GSK‐3β. They have potential applications for treating illnesses depending on GSK‐3β (hyper)activation, such as mood disorders, Alzheimer's disease, and viral infections.
- 29 September 2025
- Published by Wiley in Advanced Materials
- Vol. 38 (3) , e13858
Open AccessLithium‐Charged Gold Nanoparticles: A New Powerful Tool for Lithium Delivery and Modulation of Glycogen Synthase Kinase 3 Activity
“A Trojan Horse for Lithium Delivery” . Lithium has important pharmacological applications, although its use is severely limited due to its narrow therapeutic window of administrable concentrations. This study presents a novel nanocarrier for this metal cation based on glutathione‐stabilized gold nanoparticles (LiG‐AuNPs), which enable targeted release of lithium. LiG‐AuNPs are easily synthesized, with dimensions of ≈2 nm, with a lithium loading of 2 wt%. These particles show a tendency to aggregate and a narrow size distribution. Aggregates of LiG‐AuNPs (a‐LiG‐AuNPs) are non‐toxic to cells at concentrations lower than 2 mg mL −1 and are rapidly internalized into cells, where they release lithium in the cytosol through cation exchange, effectively modulating Glycogen Synthase Kinase‐3 (GSK‐3β) activity, especially the β isoform. Administration of a‐LiG‐AuNPs in murine models increased the inhibitory phosphorylation of GSK‐3β at Ser9. Intranasal administration of a‐LiG‐AuNPs modulated GSK‐3β activity in the brain, particularly in the hippocampus, without significantly altering plasma lithium levels, even when the administration lasted several months. LiG‐AuNPs thus represent a powerful tool for the targeted administration of lithium, enhancing its therapeutic effects in modulating GSK‐3β. They have potential applications for treating illnesses depending on GSK‐3β (hyper)activation, such as mood disorders, Alzheimer's disease, and viral infections.
- Open Access
- 16 October 2024
- Published by American Society for Microbiology in mBio
- Vol. 15 (10) , e0152224
HSV-1 infection induces phosphorylated tau propagation among neurons via extracellular vesicles
Extracellular vesicles (EV), key players in cell-to-cell communication, may contribute to disease propagation in several neurodegenerative diseases, including Alzheimer’s disease (AD), by favoring the dissemination of neurotoxic proteins within the brain. Interestingly, growing evidence supports the role of herpes simplex virus type 1 (HSV-1) infection in the pathogenesis of AD. Here, we investigated whether HSV-1 infection could promote the spread of phosphorylated tau (ptau) among neurons via EV. We analyzed the ptau species that were secreted via EV following HSV-1 infection in neuroblastoma cells and primary neurons, focusing particularly on T205, T181, and T217, the phosphorylation sites mainly associated with AD. Moreover, by overexpressing human tau tagged with GFP (htau GFP ), we found that recipient tau knockout (KO) neurons uptook EV that are loaded with HSV-1-induced phtau GFP . Finally, we exploited an in vivo model of acute infection and assessed that cerebral HSV-1 infection promotes the release of ptau via EV in the brain of infected mice. Overall, our data suggest that, following HSV-1 infection, EV play a role in tau spreading within the brain, thus contributing to neurodegeneration. IMPORTANCE: Herpes simplex virus type 1 (HSV-1) infection that reaches the brain has been repeatedly linked with the appearance of the pathognomonic markers of Alzheimer’s disease (AD), including accumulation of amyloid beta and hyperphosphorylated tau proteins, and cognitive deficits. AD is a multifactorial neurodegenerative disease representing the most common form of dementia in the elderly, and no cure is currently available, thus prompting additional investigation on potential risk factors and pathological mechanisms. Here, we demonstrate that the virus exploits the extracellular vesicles (EV) to disseminate phosphorylated tau (ptau) among brain cells. Importantly, we provide evidence that the HSV-1-induced EV-bearing ptau can be undertaken by recipient neurons, thus likely contributing to misfolding and aggregation of native tau, as reported for other AD models. Hence, our data highlight a novel mechanism exploited by HSV-1 to propagate tau-related damage in the brain.
- 16 October 2024
- Published by American Society for Microbiology in mBio
- Vol. 15 (10) , e0152224
Open AccessHSV-1 infection induces phosphorylated tau propagation among neurons via extracellular vesicles
Extracellular vesicles (EV), key players in cell-to-cell communication, may contribute to disease propagation in several neurodegenerative diseases, including Alzheimer’s disease (AD), by favoring the dissemination of neurotoxic proteins within the brain. Interestingly, growing evidence supports the role of herpes simplex virus type 1 (HSV-1) infection in the pathogenesis of AD. Here, we investigated whether HSV-1 infection could promote the spread of phosphorylated tau (ptau) among neurons via EV. We analyzed the ptau species that were secreted via EV following HSV-1 infection in neuroblastoma cells and primary neurons, focusing particularly on T205, T181, and T217, the phosphorylation sites mainly associated with AD. Moreover, by overexpressing human tau tagged with GFP (htau GFP ), we found that recipient tau knockout (KO) neurons uptook EV that are loaded with HSV-1-induced phtau GFP . Finally, we exploited an in vivo model of acute infection and assessed that cerebral HSV-1 infection promotes the release of ptau via EV in the brain of infected mice. Overall, our data suggest that, following HSV-1 infection, EV play a role in tau spreading within the brain, thus contributing to neurodegeneration. IMPORTANCE: Herpes simplex virus type 1 (HSV-1) infection that reaches the brain has been repeatedly linked with the appearance of the pathognomonic markers of Alzheimer’s disease (AD), including accumulation of amyloid beta and hyperphosphorylated tau proteins, and cognitive deficits. AD is a multifactorial neurodegenerative disease representing the most common form of dementia in the elderly, and no cure is currently available, thus prompting additional investigation on potential risk factors and pathological mechanisms. Here, we demonstrate that the virus exploits the extracellular vesicles (EV) to disseminate phosphorylated tau (ptau) among brain cells. Importantly, we provide evidence that the HSV-1-induced EV-bearing ptau can be undertaken by recipient neurons, thus likely contributing to misfolding and aggregation of native tau, as reported for other AD models. Hence, our data highlight a novel mechanism exploited by HSV-1 to propagate tau-related damage in the brain.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Crosstalk between tau and alpha7 nicotinic acetylcholine receptors at the synapse
Background: The failure of cholinergic transmission and the increase of amyloid‐β peptide (Aβ) and tau protein are key players in Alzheimer’s disease (AD). The interaction between α7 nicotinic acetylcholine receptors (α7‐nAChRs) and Aβ has been previously investigated, but few studies have focused on the crosstalk between α7‐nAChRs and tau. We previously reported that Aβ and tau might act independently or concomitantly to impair synaptic plasticity and memory, converging onto common targets such as amyloid precursor protein (APP). Here we investigated the role of α7‐nAChRs on tau‐mediated impairment of synaptic plasticity and memory, tau neuropathology, and their interplay with APP.Method: We used WT (C57Bl6/J) and α7 KO at different ages. 3XTg models of AD were used as positive controls. We performed electrophysiology to investigate synaptic transmission and plasticity at the CA3‐CA1 synapses from hippocampal slices, and behavioral studies (Novel Object Recognition and Location, Fear Conditioning) to evaluate memory. We used western blot for the expression of APP, tau (Ser199, Ser396, Thr205) and GSK‐3β (Ser9) phosphorylation. Formation of tau paired helical filaments (PHFs) and neurofibrillary tangles (NFTs) were evaluated by immunohistochemistry and Bielschowsky staining. Immunoreactivity for NeuN was measured to assess neuronal loss.Result: We found that α7 KO mice presented an AD phenotype characterized by the impairment of Long‐Term Potentiation and Paired Pulse Facilitation, and the reduction of different types of memory starting at 12 months of age. This age‐dependent phenotype was paralleled by an increase of APP expression, hyperphosphorylation of tau, and a decrease of GSK‐3β (Ser9) phosphorylation. α7 KO hippocampi presented a marked tau neuropathology with an increase of PHF‐1 immunoreactivity, the presence of PHFs and NFTs, and neuronal loss.Conclusion: In summary, the lack of α7‐nAChRs was sufficient to trigger an AD‐like phenotype characterized by a marked tau pathology. Our data also suggest that the concomitant increase of APP expression might contribute to tau neurotoxicity.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessCrosstalk between tau and alpha7 nicotinic acetylcholine receptors at the synapse
Background: The failure of cholinergic transmission and the increase of amyloid‐β peptide (Aβ) and tau protein are key players in Alzheimer’s disease (AD). The interaction between α7 nicotinic acetylcholine receptors (α7‐nAChRs) and Aβ has been previously investigated, but few studies have focused on the crosstalk between α7‐nAChRs and tau. We previously reported that Aβ and tau might act independently or concomitantly to impair synaptic plasticity and memory, converging onto common targets such as amyloid precursor protein (APP). Here we investigated the role of α7‐nAChRs on tau‐mediated impairment of synaptic plasticity and memory, tau neuropathology, and their interplay with APP.Method: We used WT (C57Bl6/J) and α7 KO at different ages. 3XTg models of AD were used as positive controls. We performed electrophysiology to investigate synaptic transmission and plasticity at the CA3‐CA1 synapses from hippocampal slices, and behavioral studies (Novel Object Recognition and Location, Fear Conditioning) to evaluate memory. We used western blot for the expression of APP, tau (Ser199, Ser396, Thr205) and GSK‐3β (Ser9) phosphorylation. Formation of tau paired helical filaments (PHFs) and neurofibrillary tangles (NFTs) were evaluated by immunohistochemistry and Bielschowsky staining. Immunoreactivity for NeuN was measured to assess neuronal loss.Result: We found that α7 KO mice presented an AD phenotype characterized by the impairment of Long‐Term Potentiation and Paired Pulse Facilitation, and the reduction of different types of memory starting at 12 months of age. This age‐dependent phenotype was paralleled by an increase of APP expression, hyperphosphorylation of tau, and a decrease of GSK‐3β (Ser9) phosphorylation. α7 KO hippocampi presented a marked tau neuropathology with an increase of PHF‐1 immunoreactivity, the presence of PHFs and NFTs, and neuronal loss.Conclusion: In summary, the lack of α7‐nAChRs was sufficient to trigger an AD‐like phenotype characterized by a marked tau pathology. Our data also suggest that the concomitant increase of APP expression might contribute to tau neurotoxicity.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
APP/AICD‐dependent expression of Glypican 4 mediates accumulation of tau oligomers in astrocytes and their synaptotoxic action
Background: Several studies including ours reported the detrimental effects of extracellular tau oligomers (ex‐oTau) on glutamatergic synaptic transmission and plasticity. Astrocytes greatly internalize ex‐oTau thus contributing to their clearance. However, glial cell engulfment of oTau leads to alteration of neuro/gliotransmitter handling that negatively affects synaptic function. We previously reported that amyloid precursor protein (APP) is required for oTau internalization in astrocytes but the molecular mechanisms underlying this phenomenon has not been clearly identified yet. Here we investigated the role of glypican 4 (GPC4), a member of the large family of heparan sulfate proteoglycans that are membrane glycoproteins highly expressed in astrocytes playing a critical role in protein trafficking through the plasma membrane.Method: The role of GPC4 in ex‐oTau accumulation in astrocytes and the resulting synaptotoxic action were studied in in vitro and ex‐vivo models obtained from wild‐type C57/bl6 and transgenic mice in which either APP was knocked‐out or it contained the non‐phosphorylatable amino acid alanine replacing threonine 688 (APPTA mice). In these experimental models we performed immunofluorescence analyses, Western blot and real‐time PCR experiments, confocal Ca2+ imaging, high‐pressure liquid chromatography, FM1‐43 imaging, electrophysiological recordings and Chromatin immunoprecipitation assays.Result: Treatment of cultured astrocytes with a specific anti‐GPC4 antibody significantly reduced oTau internalization in astrocytes and prevented oTau‐induced alterations of intracellular Ca2+ signaling and gliotransmitter release. As such, anti‐GPC4 treatment spared neurons from the astrocyte‐mediated synaptotoxic action of ex‐oTau. Specifically, after counteracting the interaction between ex‐oTau and GPC4 no significant decreases in synaptic vesicular release and synaptic protein expression were observed in neurons co‐cultured with astrocytes following exposure to ex‐oTau. The latter also failed to inhibit hippocampal LTP at CA3‐CA1 synapses. Of note, we found that the expression of GPC4 depended on APP and, in particular, on its C‐terminal domain, AICD, generated by γ‐secretase‐dependent cleavage of APP, that can bind Gpc4 promoter. Accordingly, GPC4 expression was significantly reduced in both APP‐KO ad APPTA mice, and ex‐oTau did not exert any significant detrimental action on synaptic function in APP‐KO mice.Conclusion: Collectively, our data indicate that GPC4 expression is APP/AICD‐dependent, it mediates oTau accumulation in astrocytes and the resulting synaptotoxic effects.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Open AccessAPP/AICD‐dependent expression of Glypican 4 mediates accumulation of tau oligomers in astrocytes and their synaptotoxic action
Background: Several studies including ours reported the detrimental effects of extracellular tau oligomers (ex‐oTau) on glutamatergic synaptic transmission and plasticity. Astrocytes greatly internalize ex‐oTau thus contributing to their clearance. However, glial cell engulfment of oTau leads to alteration of neuro/gliotransmitter handling that negatively affects synaptic function. We previously reported that amyloid precursor protein (APP) is required for oTau internalization in astrocytes but the molecular mechanisms underlying this phenomenon has not been clearly identified yet. Here we investigated the role of glypican 4 (GPC4), a member of the large family of heparan sulfate proteoglycans that are membrane glycoproteins highly expressed in astrocytes playing a critical role in protein trafficking through the plasma membrane.Method: The role of GPC4 in ex‐oTau accumulation in astrocytes and the resulting synaptotoxic action were studied in in vitro and ex‐vivo models obtained from wild‐type C57/bl6 and transgenic mice in which either APP was knocked‐out or it contained the non‐phosphorylatable amino acid alanine replacing threonine 688 (APPTA mice). In these experimental models we performed immunofluorescence analyses, Western blot and real‐time PCR experiments, confocal Ca2+ imaging, high‐pressure liquid chromatography, FM1‐43 imaging, electrophysiological recordings and Chromatin immunoprecipitation assays.Result: Treatment of cultured astrocytes with a specific anti‐GPC4 antibody significantly reduced oTau internalization in astrocytes and prevented oTau‐induced alterations of intracellular Ca2+ signaling and gliotransmitter release. As such, anti‐GPC4 treatment spared neurons from the astrocyte‐mediated synaptotoxic action of ex‐oTau. Specifically, after counteracting the interaction between ex‐oTau and GPC4 no significant decreases in synaptic vesicular release and synaptic protein expression were observed in neurons co‐cultured with astrocytes following exposure to ex‐oTau. The latter also failed to inhibit hippocampal LTP at CA3‐CA1 synapses. Of note, we found that the expression of GPC4 depended on APP and, in particular, on its C‐terminal domain, AICD, generated by γ‐secretase‐dependent cleavage of APP, that can bind Gpc4 promoter. Accordingly, GPC4 expression was significantly reduced in both APP‐KO ad APPTA mice, and ex‐oTau did not exert any significant detrimental action on synaptic function in APP‐KO mice.Conclusion: Collectively, our data indicate that GPC4 expression is APP/AICD‐dependent, it mediates oTau accumulation in astrocytes and the resulting synaptotoxic effects.
- Open Access
- 1 June 2023
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 80 (6) , 1-14
Interleukin 1β triggers synaptic and memory deficits in Herpes simplex virus type-1-infected mice by downregulating the expression of synaptic plasticity-related genes via the epigenetic MeCP2/HDAC4 complex
Extensive research provides evidence that neuroinflammation underlies numerous brain disorders. However, the molecular mechanisms by which inflammatory mediators determine synaptic and cognitive dysfunction occurring in neurodegenerative diseases (e.g., Alzheimer’s disease) are far from being fully understood. Here we investigated the role of interleukin 1β (IL-1β), and the molecular cascade downstream the activation of its receptor, to the synaptic dysfunction occurring in the mouse model of multiple Herpes simplex virus type-1 (HSV-1) reactivations within the brain. These mice are characterized by neuroinflammation and memory deficits associated with a progressive accumulation of neurodegenerative hallmarks (e.g., amyloid-β protein and tau hyperphosphorylation). Here we show that mice undergone two HSV-1 reactivations in the brain exhibited increased levels of IL-1β along with significant alterations of: (1) cognitive performances; (2) hippocampal long-term potentiation; (3) expression synaptic-related genes and pre- and post-synaptic proteins; (4) dendritic spine density and morphology. These effects correlated with activation of the epigenetic repressor MeCP2 that, in association with HDAC4, affected the expression of synaptic plasticity-related genes. Specifically, in response to HSV-1 infection, HDAC4 accumulated in the nucleus and promoted MeCP2 SUMOylation that is a post-translational modification critically affecting the repressive activity of MeCP2. The blockade of IL-1 receptors by the specific antagonist Anakinra prevented the MeCP2 increase and the consequent downregulation of gene expression along with rescuing structural and functional indices of neurodegeneration. Collectively, our findings provide novel mechanistic evidence on the role played by HSV-1-activated IL-1β signaling pathways in synaptic deficits leading to cognitive impairment.
- 1 June 2023
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 80 (6) , 1-14
Open AccessInterleukin 1β triggers synaptic and memory deficits in Herpes simplex virus type-1-infected mice by downregulating the expression of synaptic plasticity-related genes via the epigenetic MeCP2/HDAC4 complex
Extensive research provides evidence that neuroinflammation underlies numerous brain disorders. However, the molecular mechanisms by which inflammatory mediators determine synaptic and cognitive dysfunction occurring in neurodegenerative diseases (e.g., Alzheimer’s disease) are far from being fully understood. Here we investigated the role of interleukin 1β (IL-1β), and the molecular cascade downstream the activation of its receptor, to the synaptic dysfunction occurring in the mouse model of multiple Herpes simplex virus type-1 (HSV-1) reactivations within the brain. These mice are characterized by neuroinflammation and memory deficits associated with a progressive accumulation of neurodegenerative hallmarks (e.g., amyloid-β protein and tau hyperphosphorylation). Here we show that mice undergone two HSV-1 reactivations in the brain exhibited increased levels of IL-1β along with significant alterations of: (1) cognitive performances; (2) hippocampal long-term potentiation; (3) expression synaptic-related genes and pre- and post-synaptic proteins; (4) dendritic spine density and morphology. These effects correlated with activation of the epigenetic repressor MeCP2 that, in association with HDAC4, affected the expression of synaptic plasticity-related genes. Specifically, in response to HSV-1 infection, HDAC4 accumulated in the nucleus and promoted MeCP2 SUMOylation that is a post-translational modification critically affecting the repressive activity of MeCP2. The blockade of IL-1 receptors by the specific antagonist Anakinra prevented the MeCP2 increase and the consequent downregulation of gene expression along with rescuing structural and functional indices of neurodegeneration. Collectively, our findings provide novel mechanistic evidence on the role played by HSV-1-activated IL-1β signaling pathways in synaptic deficits leading to cognitive impairment.
- Open Access
- 16 March 2022
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 48 (5) , e12811
Extracellular tau oligomers affect extracellular glutamate handling by astrocytes through downregulation of GLT‐1 expression and impairment of NKA1A2 function
Aims: Several studies reported that astrocytes support neuronal communication by the release of gliotransmitters, including ATP and glutamate. Astrocytes also play a fundamental role in buffering extracellular glutamate in the synaptic cleft, thus limiting the risk of excitotoxicity in neurons. We previously demonstrated that extracellular tau oligomers (ex‐oTau), by specifically targeting astrocytes, affect glutamate‐dependent synaptic transmission via a reduction in gliotransmitter release. The aim of this work was to determine if ex‐oTau also impair the ability of astrocytes to uptake extracellular glutamate, thus further contributing to ex‐oTau‐dependent neuronal dysfunction.Methods: Primary cultures of astrocytes and organotypic brain slices were exposed to ex‐oTau (200 nM) for 1 h. Extracellular glutamate buffering by astrocytes was studied by: Na+ imaging; electrophysiological recordings; high‐performance liquid chromatography; Western blot and immunofluorescence. Experimental paradigms avoiding ex‐oTau internalisation (i.e. heparin pre‐treatment and amyloid precursor protein knockout astrocytes) were used to dissect intracellular vs extracellular effects of oTau.Results: Ex‐oTau uploading in astrocytes significantly affected glutamate‐transporter‐1 expression and function, thus impinging on glutamate buffering activity. Ex‐oTau also reduced Na‐K‐ATPase activity because of pump mislocalisation on the plasma membrane, with no significant changes in expression. This effect was independent of oTau internalisation and it caused Na+ overload and membrane depolarisation in ex‐oTau‐targeted astrocytes.Conclusions: Ex‐oTau exerted a complex action on astrocytes, at both intracellular and extracellular levels. The net effect was dysregulated glutamate signalling in terms of both release and uptake that relied on reduced expression of glutamate‐transporter‐1, altered function and localisation of NKA1A1, and NKA1A2. Consequently, Na+ gradients and all Na+‐dependent transports were affected.
- 16 March 2022
- Published by Wiley in Neuropathology and Applied Neurobiology
- Vol. 48 (5) , e12811
Open AccessExtracellular tau oligomers affect extracellular glutamate handling by astrocytes through downregulation of GLT‐1 expression and impairment of NKA1A2 function
Aims: Several studies reported that astrocytes support neuronal communication by the release of gliotransmitters, including ATP and glutamate. Astrocytes also play a fundamental role in buffering extracellular glutamate in the synaptic cleft, thus limiting the risk of excitotoxicity in neurons. We previously demonstrated that extracellular tau oligomers (ex‐oTau), by specifically targeting astrocytes, affect glutamate‐dependent synaptic transmission via a reduction in gliotransmitter release. The aim of this work was to determine if ex‐oTau also impair the ability of astrocytes to uptake extracellular glutamate, thus further contributing to ex‐oTau‐dependent neuronal dysfunction.Methods: Primary cultures of astrocytes and organotypic brain slices were exposed to ex‐oTau (200 nM) for 1 h. Extracellular glutamate buffering by astrocytes was studied by: Na+ imaging; electrophysiological recordings; high‐performance liquid chromatography; Western blot and immunofluorescence. Experimental paradigms avoiding ex‐oTau internalisation (i.e. heparin pre‐treatment and amyloid precursor protein knockout astrocytes) were used to dissect intracellular vs extracellular effects of oTau.Results: Ex‐oTau uploading in astrocytes significantly affected glutamate‐transporter‐1 expression and function, thus impinging on glutamate buffering activity. Ex‐oTau also reduced Na‐K‐ATPase activity because of pump mislocalisation on the plasma membrane, with no significant changes in expression. This effect was independent of oTau internalisation and it caused Na+ overload and membrane depolarisation in ex‐oTau‐targeted astrocytes.Conclusions: Ex‐oTau exerted a complex action on astrocytes, at both intracellular and extracellular levels. The net effect was dysregulated glutamate signalling in terms of both release and uptake that relied on reduced expression of glutamate‐transporter‐1, altered function and localisation of NKA1A1, and NKA1A2. Consequently, Na+ gradients and all Na+‐dependent transports were affected.
- Open Access
- 1 November 2021
- Published by Elsevier in Progress in Neurobiology
- Vol. 206, 102154
Genetic deletion of α7 nicotinic acetylcholine receptors induces an age-dependent Alzheimer’s disease-like pathology
- 1 November 2021
- Published by Elsevier in Progress in Neurobiology
- Vol. 206, 102154
Open AccessGenetic deletion of α7 nicotinic acetylcholine receptors induces an age-dependent Alzheimer’s disease-like pathology
- Top Cited PapersOpen Access
- 1 October 2020
- Published by Elsevier in Trends in Microbiology
- Vol. 28 (10) , 808-820
Herpes Simplex Virus-1 in the Brain: The Dark Side of a Sneaky Infection
- 1 October 2020
- Published by Elsevier in Trends in Microbiology
- Vol. 28 (10) , 808-820
Top Cited PapersOpen AccessHerpes Simplex Virus-1 in the Brain: The Dark Side of a Sneaky Infection
Ca2+‐dependent release of ATP from astrocytes affects herpes simplex virus type 1 infection of neurons
Astrocytes provide metabolic support for neurons and modulate their functions by releasing a plethora of neuroactive molecules diffusing to neighboring cells. Here we report that astrocytes also play a role in cortical neurons' vulnerability to Herpes simplex virus type‐1 (HSV‐1) infection through the release of extracellular ATP. We found that the interaction of HSV‐1 with heparan sulfate proteoglycans expressed on the plasma membrane of astrocytes triggered phospholipase C‐mediated IP3‐dependent intracellular Ca2+ transients causing extracellular release of ATP. ATP binds membrane purinergic P2 receptors (P2Rs) of both neurons and astrocytes causing an increase in intracellular Ca2+ concentration that activates the Glycogen Synthase Kinase (GSK)‐3β, whose action is necessary for HSV‐1 entry/replication in these cells. Indeed, in co‐cultures of neurons and astrocytes HSV‐1‐infected neurons were only found in proximity of infected astrocytes releasing ATP, whereas in the presence of fluorocitrate, an inhibitor of astrocyte metabolism, switching‐off the HSV‐1‐induced ATP release, very few neurons were infected. The addition of exogenous ATP, mimicking that released by astrocytes after HSV‐1 challenge, restored the ability of HSV‐1 to infect neurons co‐cultured with metabolically‐inhibited astrocytes. The ATP‐activated, P2R‐mediated, and GSK‐3‐dependent molecular pathway underlying HSV‐1 infection is likely shared by neurons and astrocytes, given that the blockade of either P2Rs or GSK‐3 activation inhibited infection of both cell types. These results add a new layer of information to our understanding of the critical role played by astrocytes in regulating neuronal functions and their response to noxious stimuli including microbial agents via Ca2+‐dependent release of neuroactive molecules.
Ca2+‐dependent release of ATP from astrocytes affects herpes simplex virus type 1 infection of neurons
Astrocytes provide metabolic support for neurons and modulate their functions by releasing a plethora of neuroactive molecules diffusing to neighboring cells. Here we report that astrocytes also play a role in cortical neurons' vulnerability to Herpes simplex virus type‐1 (HSV‐1) infection through the release of extracellular ATP. We found that the interaction of HSV‐1 with heparan sulfate proteoglycans expressed on the plasma membrane of astrocytes triggered phospholipase C‐mediated IP3‐dependent intracellular Ca2+ transients causing extracellular release of ATP. ATP binds membrane purinergic P2 receptors (P2Rs) of both neurons and astrocytes causing an increase in intracellular Ca2+ concentration that activates the Glycogen Synthase Kinase (GSK)‐3β, whose action is necessary for HSV‐1 entry/replication in these cells. Indeed, in co‐cultures of neurons and astrocytes HSV‐1‐infected neurons were only found in proximity of infected astrocytes releasing ATP, whereas in the presence of fluorocitrate, an inhibitor of astrocyte metabolism, switching‐off the HSV‐1‐induced ATP release, very few neurons were infected. The addition of exogenous ATP, mimicking that released by astrocytes after HSV‐1 challenge, restored the ability of HSV‐1 to infect neurons co‐cultured with metabolically‐inhibited astrocytes. The ATP‐activated, P2R‐mediated, and GSK‐3‐dependent molecular pathway underlying HSV‐1 infection is likely shared by neurons and astrocytes, given that the blockade of either P2Rs or GSK‐3 activation inhibited infection of both cell types. These results add a new layer of information to our understanding of the critical role played by astrocytes in regulating neuronal functions and their response to noxious stimuli including microbial agents via Ca2+‐dependent release of neuroactive molecules.